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Absence of β2 integrins (CD11/CD18) leads to leukocyte-adhesion deﬁciency-1 (LAD1), a rare primary immunodeﬁciency syn-
drome.Althoughextensiveinvitroworkhasestablishedanessentialfunctionofβ2 integrinsinadhesiveandsignalingpropertiesfor
cellsoftheinnateandadaptiveimmunesystem,theirrespectiveparticipationinanalteredadaptiveimmunityinLAD1patientsare
complex and only partly understoodinvivo. Therefore,weinvestigated adaptive immuneresponsestowards diﬀerent T-dependent
antigens in a murine LAD1 model of β2 integrin-deﬁciency (CD18−/−). CD18−/− mice generated only weak IgG responses after
immunization with tetanus toxoid (TT). In contrast, robust hapten- and protein-speciﬁc immune responses were observed after
immunization with highly haptenated antigens such as (4-hydroxy-3-nitrophenyl)21 acetyl chicken γ globulin (NP21-CG), even
though regularly structured germinal centers with speciﬁcity for the deﬁned antigens/haptens in CD18−/− mice remained absent.
However, a decrease in the hapten/protein ratio lowered the eﬃcacy of immune responses in CD18−/− mice, whereas a mere
reduction of the antigen dose was less crucial. Importantly, haptenation of TT with NP (NP-TT) eﬃciently restored a robust IgG
responsealsotoTT.Ourﬁndingsmaystimulatefurtherstudiesonamodiﬁcationofvaccinationstrategiesusinghighlyhaptenated
antigens in individuals suﬀering from LAD1.2 Clinical and Developmental Immunology
1.Introduction
Adaptive immune responses require the integration of
complex antigen receptor and costimulatory signals on T
cells as well as B cells to override activation thresholds
that lead to lymphocyte diﬀerentiation and eventually, to
antibody production. The β2 integrin LFA-1 (CD11a/CD18)
is particularly prominent in promoting the interaction
between APC and na¨ ıve T cells [1]a sw e l la sb e t w e e nTc e l l s
and B cells [2, 3]. In this, LFA-1 signaling is an important
determinant of phenotypic outcome in na¨ ıve T-cell and B-
cell maturation and eﬀector function [4–6].
A prerequisite for T-cell activation is a stable T-cell
stimulation which is essential to be sustained up to several
hours[4]toachievecommitmenttocytokinesynthesis(IL-2,
IFN-γ)[ 7–9]. It has been reported that the duration of
stimulation directly contributes to the commitment of CD4+
T cells to division thus correlating with the development
of eﬀector functions and the extent of memory generation
[10]. Furthermore, it has been assumed that the adhesive
interaction mediated by LFA-1 increases the avidity of
T cell:APC interaction allowing T cells to sample large
numbers of speciﬁc peptides presented on MHC class II on
the surface of APC which then leads to a more eﬃcient TCR
engagement. Increased adhesion can thus lower the eﬀective
dose of antigen required to reach a minimal threshold
number of activated TCR complexes [1, 5, 11, 12]. Further-
more, LFA-1 facilitates the clustering of surface molecules
such as the TCR, CD28, and CD40 in the immunological
synapse between T cells and APC (quantitative signal
enhancement) [13, 14]. In addition to its above-described
adhesive functions, LFA-1 may also provide unique signals
that are primarily independent of TCR signaling (qualitative
signal modulation) [5, 8]. Model systems used to study
T-cell activation have shown that even a mere increase
in antigen “quantity” at a large scale could not initiate
na¨ ıve CD4+ T-cell proliferation or cytokine synthesis in the
absence of ICAM/LFA-1 interaction [15]. Collectively, it is
well established that LFA-1 stimulation increases the number
of activated T cells favoring Th1 diﬀerentiation, distinctly
enhances activation velocity in particular by supporting
early IL-2 production, leading to entry of na¨ ıve cells into
the cell cycle and reduces activation thresholds of T cells.
Hence, LFA-1/ICAM signaling signiﬁcantly supports T-cell
activation and polarization towards the Th1 phenotype [5,
7]. In the absence of functional LFA-1, Th1 diﬀerentiation
is severely impaired, whereas Th2 response is strongly
enhanced, both in vitro and in vivo [9, 16, 17].
Interestingly, the relevance of LFA-1/ICAM for T:B
immunological synapses has also been documented for
membrane-mediated B-cell activation by Th cells [2]. Sig-
naling from antigen-speciﬁc T cells to B cells to induce
activation required LFA-1/ICAM-1 ligation and is based
on tight physical contact of T:B in an immune synapse
[18]. In this context, Carrasco and coworkers showed that
inclusionofICAM-1intheimmunologicalsynapsedecreases
the B-cell avidity threshold by at least 10-fold [2]. At low
antigen densities, LFA-1 can help B-cells adhering, forming
a synapse, and becoming activated. Thus, in analogy to
the T cell:APC interaction, synergy of BCR crosslinking
and ICAM-1-mediated signals can reduce threshold barriers
for B-cell activation. Vice versa, eﬀective B:T cell synapses
are of even greater importance for T-cell activation by
antigen-presenting B cells (B-APC). Engagement of the BCR
by polyvalent antigen can rapidly elicit expression of B7-
2 (CD86) on B cells resulting in a robust costimulatory
signal that is suﬃcient even to drive na¨ ıve Th cell responses
[19, 20].
Although detailed studies on the adhesive and dif-
ferentiation-inducing functions of LFA-1-mediated binding
for APC:T cell and T:B cell contacts are available, it still
remains incompletely understood how the observed in vitro
functions combine and contribute to the clinical picture of
immunodeﬁciency in individuals lacking β2 integrins in vivo.
Absence of β2 integrins (CD11/CD18) in humans leads to
leukocyte-adhesion deﬁciency-1 (LAD1), a severe primary
immunodeﬁciency syndrome. Expression of less than 1% of
CD18 causes a severe form of the disease with recurrent life-
threatening bacterial or fungal infections resulting in death
of patients early in childhood [21, 22]. Impaired adaptive
immune responses to common vaccination protocols have
been observed as one important feature of the disease
[23, 24]. We have previously reported on a murine model
for LAD1 carrying a CD18 null mutation that shares all
major features with the human syndrome [25–29]. Using
this murine model, we herein dissect the role of β2 integrins
in functional and structural components of the adaptive
immune response in vivo.
Our results demonstrate that in absence of β2 inte-
grins, mice display a severely impaired adaptive immune
response in vivo. A marked elevation of activation thresh-
olds excluded the commonly potent antigen TT as an
immunogen, whereas haptenation of carrier proteins could
override the activation threshold and elicited robust adaptive
immune responses. These ﬁndings indicate that modifying
vaccination approaches towards the use of highly haptenated
antigens may be more successful in LAD1 patients.
2.MaterialsandMethods
2.1. Mice. All mice were maintained on a mixed
129Sv × C57BL/6 background. CD18−/− homozygotes [25]
and CD18+/+ WT controls were derived from heterozygote
crosses. Immunization trials were performed under speciﬁc
pathogen-free (SPF) conditions using mice at an age of 8–12
weeks. All experiments were done in compliance with the
German Law for Welfare of Laboratory Animals.
2.2. Immunization of CD18−/− Mice. For immunization of
mice, protein antigens conjugated with a hapten at diﬀerent
haptenationratioswereused.Thesehapten-coupledproteins
were prepared according to a previously established protocol
[30, 31]. In brief, per animal, a solution of 200μL PBS
containing 10 or 100μg of (4-hydroxy-3-nitrophenyl) acetyl
(NP; Bioresearch Technologies, Inc., Novato, CA) coupled to
chicken γ globulin(CG;Calbiochem,Schwalbach,Germany)
with a ratio of 21 or 4 NP molecules per molecule CG was
precipitated by adding 200μL 10% KAl(SO4)2 (alum; MerckClinical and Developmental Immunology 3
Chemicals, Darmstadt, Germany) and was then titrated
using 5N NaOH. Or else, uncoupled CG was precipitated.
The alum precipitates were injected intraperitoneally into
mice. All animals were reinjected with 10 or 100μg of the
soluble, unprecipitated NP-CG or CG at the indicated time
points.
Immunization with tetanus toxoid (TT) was performed
in a similar fashion. “Tetanus-Impfstoﬀ M´ erieux” vaccina-
tion suspension was purchased from Aventis Pasteur MSD
(Lyon, France). Eight- to tewlve-week-old mice were injected
with a dose of either 2.0Lf (ﬂocculation units) or 0.2Lf
of alum-precipitated TT. In a further trial, mice were
immunized with 2.0Lf of alum-precipitated TT haptenated
with NP molecules at an unknown ratio, according to a
previously published protocol for the hapten conjugation of
protein carrier molecules [30, 31]. All mice were reinjected
with the same dose of TT or NP-TT, respectively, at indicated
time points of the trials.
2.3. Measurement of NP-Speciﬁc Ig. Immune responses were
estimated by ELISA detection of NP hapten-speciﬁc IgM,
IgG1, κ,a n dλ light chain Ab in the sera of mice immunized




obtained at the indicated time points after immunization
were added and incubated at 4◦C overnight. On each plate,
equally diluted anti-NP mAb standards with corresponding
isotypes (prepared at the Institute of Genetics, University
of Cologne according to previously published protocols [30,
31]) were included to obtain appropriate standard curves.
After intermittent washing steps with H2O, biotinylated
detection antibodies (goat anti-mouse IgM, IgG, κ and
λ; Southern Biotechnology Associates Inc., Birmingham,
AL) at a dilution of 1:1000 and alkaline-phosphatase-
(ALP-) conjugated streptavidin (1:3000; Roche, Mannheim,
Germany)wereadded.ALPactivitywasvisualizedusingALP
substratesolution(0.4mg/mL;Roche)andsubsequently,OD
was measured at 405nm versus 570nm. The concentrations
were determined by comparing to standard curves created
from above mentioned anti-NP standards.
2.4. Aﬃnity Maturation of NP-Speciﬁc Antibodies. Assess-
ment of aﬃnity maturation of NP-speciﬁc antibodies was
carried out by ELISA using two diﬀerent coupling ratios
of NP-BSA as described previously [32, 33]. Brieﬂy, 96-
well plates (Greiner) were coated with 10μg/mL NP4-BSA
or NP14-BSA in PBS at 4◦C overnight. After blocking with
0.5% BSA in PBS, sera obtained at the indicated time points
after immunizations were serially diluted and plated out.
On each plate, anti-NP-speciﬁc mAb standards of the same
isotype but with diﬀerent aﬃnity constants (Ka)( p r e p a r e d
at the Institute of Genetics, University of Cologne according
to previously published protocols [30, 31]) were added to
obtainstandardcurvesforaﬃnityassessment.Theﬁnalsteps
of the ELISA were then performed as described above using
biotinylatedgoatanti-mouseλlightchainandIgG1 (datanot
shown) detection Ab. To estimate the aﬃnity of NP-binding
antibodyinthesera,ratiosofNP4-bindingantibodytoNP14-
binding antibody were calculated.
2.5. Measurement of Protein-Carrier-Speciﬁc IgG. For assess-
ment of anti-TT- or anti-CG-speciﬁc IgG Ab, sera obtained
by bleeding from tail veins were analyzed by ELISA. Brieﬂy,
for anti-TT detection, human Tetanus IgG ELISA kits
were purchased from IBL (Hamburg, Germany) and ELISA
performed according to a slightly modiﬁed protocol, as
distributed by the manufacturer. Sera were initially diluted
1:10 in assay diluent and subsequently plated out in 1:5
or 1:6 dilution steps using assay diluent. For detection
of murine anti-TT IgG Ab, a horseradish peroxidase-
conjugated rat anti-mouse IgG mAb (X56; Pharmingen, BD,
Heidelberg, Germany) was used at a dilution of 1:1000.
Tetramethylbenzidine (TMB, IBL) served as a substrate for
the color reaction. Plates were read at 450nm within 60
minutes after addition of 1M H2SO4. Anti-TT IgG titers
were calculated from the last dilution step where the OD
wasstill above the background level. Assays formeasurement
of anti-CG IgG were performed accordingly, except with
the modiﬁcation that, initially, 96-well plates (Greiner) were
coated with 10μg/mL soluble CG in PBS and were blocked
with 0.5% BSA. Subsequently, all further procedures were
carried out as described above.
2.6. Antibodies and Fluorochrome-Coupled Proteins. GL7-
FITC (Ly77), CD18-PE (C71/16) mAbs were purchased
from Pharmingen, CD19-PE (6D5) was from SBA, and
IgD (HB250) and IgM (HB88) were obtained as described
earlier [34]. Peanut agglutinin (PNA)-FITC was purchased
from Sigma (Taufkirchen, Germany) and DAPI from Roche
(Grenzach-Wyhlen, Germany).
For detection of antigen-speciﬁc cells, NP4-CG and CG
werelabeledwithCychrome5(Cy5),andconjugatespuriﬁed
using NAP columns, as recommended by the manufacturer
(Amersham/Pharmacia, Freiburg, Germany). NP4-CG and
CGwereusedinsteadofNP21-CGforﬂuorochromecoupling
to allow suﬃcient binding of Cy5 to free sites of the CG.
2.7. Histology. Spleens were removed at the indicated time
points after immunization and were embedded in Tissue-
TekO.C.T.compound(FisherScientiﬁc,Bridgewater,NJ)for
cryosections. Immunohistologic analysis of adult lymphoid
tissues was done as described earlier [34] using a motorized
Axiovert M200 microscope (Carl Zeiss, Germany). Frozen
sections of 6–10μm thickness were mounted on slides and
ﬁxed in cold acetone. Cryosections were blocked with rat
serumandstainedwithmAbandlectinsagainsttheindicated
markers. Overviews of spleen sections shown in Figure 3(a)
were achieved using automated image assembly applying the
KS300 MosaiX software (Carl Zeiss, Oberkochen, Germany).
2.8. FACS Analysis. Cells were obtained from spleens, or
from BM ﬂushed out of femurs of mice. Red blood cells
were removed using an osmotic lysis buﬀer (0.15M NH4Cl,
1.0M KHCO3,0 . 1 MN a 2EDTA, pH 7.2). The remaining4 Clinical and Developmental Immunology
leukocyte fraction was adjusted to 1 × 106 cells per 50μL
and unspeciﬁc binding was blocked with 2% rat serum.
Subsequently, 50μL of the cell suspension were stained with
≤1μL of the ﬂuorochrome-conjugated mAbs (at a stock
concentration of 0.5–1mg/mL, dependent on the respective
mAb-ﬂuorochrome conjugate) for 30min at 4◦C. Stained
cells were analyzed using a FACSCalibur (BD, Heidelberg,
Germany).
2.9. Statistics. For statistical evaluation of the diﬀerences in
serum Ig levels, Mann-Whitney U test was used. Diﬀerences
were considered statistically signiﬁcant when P<0.05.
3. Results
3.1. Impaired Humoral Immune Response in CD18−/− Mice
upon Immunization with Tetanus Toxoid. LAD1 patients
suﬀer from a severe immunodeﬁciency due to an absence
of functional CD18 heterodimers. Patients [23, 24]a sw e l l
as cattle [35]d e ﬁ c i e n ti nC D 1 8h a v eb e e nd e s c r i b e dt o
respond poorly to T-dependent antigens or vaccines such
as bacteriophage φX174 or tetanus toxoid (TT). Since TT
is a well-characterized and commonly potent immunogen
that has been frequently employed to detect T-dependent
immunodeﬁciency by others before, we determined anti-TT
IgG titers in a TT vaccination trial in the murine LAD1
model. CD18−/− and WT mice were immunized with either
2.0 or 0.2 ﬂocculation units (Lf) of TT/alum. For assessment
of memory B-cell function and ampliﬁcation of speciﬁc
Ig production during secondary immune response, animals
wereboost-immunized with the same doses at day 34. Serum
levelsofanti-TTIgGweredetectedbyELISAatdiﬀerenttime
points throughout the trial. At all time points analyzed, anti-
TT IgG titers were signiﬁcantly lower in CD18−/− mice than
in WT controls independent of the TT dose injected (P<
0.05)(Figure 1).Aftersecondaryimmunization,anti-TTIgG
titers of CD18−/− mice were about three logs below WT
control titers. Whereas in WT mice a strong ampliﬁcation of
the immune response occurred, CD18−/− mice were not able
to amplify their anti-TT IgG production any further after
reimmunization with the antigen. However, TT-speciﬁc IgG
titersweremeasurablealsoinCD18−/− mice,conﬁrmingthat
class switch was not impaired.
3.2. Robust T-Dependent Humoral Immune Response in
CD18−/− Mice upon Immunization with NP-CG. To address
the question, whether defective adaptive immunity in
CD18−/− mice relied on particular TT-speciﬁc properties,
CD18−/− and WT mice were immunized with the alum-
precipitated antigen NP21-CG at a dose as high as 100μg
per mouse, in an analogous immunization trial. For mea-
surement of memory B-cell function and ampliﬁcation of
speciﬁc Ig production during secondary immune response,
animals were boost-immunized with 100μgo fs o l u b l eN P 21-
CG at day 34. Serum levels of anti-NP-speciﬁc Ig were
detected and further diﬀerentiated into subclasses by ELISA.
Surprisingly, a slightly lower production of anti-NP IgG1
was detectable only during the primary immune response
CD18 TT
(Lf)
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Figure 1: Defective humoral immune response upon TT in
CD18−/− mice. Eight- to twelve-week-old CD18−/− (open symbols)
and WT (ﬁlled symbols) mice were immunized intraperitoneally
with 2.0 (squares) or 0.2Lf (circles) of tetanus toxoid (TT)/alum.
Animals were reimmunized with the same dose of the antigen at
day 34. For assessment of the primary immune response, sera were
collected at days 0, 7, and 14, for secondary immune response at
days34,42,and49.Subsequently,serawerediluted1:10,andplated
out on TT-coated plates in 1:6 dilution steps. Serum titers of anti-
TT speciﬁc IgG1 were determined from the last dilution step where
the optical density was still above the background level of the assay.
Bars represent the median of each group. ∗Indicates a P<0.05 for
the marked cohorts at all times points shown, from day 14 on.
in CD18−/− mice (Figure 2(a)). At day 7, titers of CD18−/−
mice were about 4.5-fold reduced when compared to WT
controls (P<0.005), whereas at day 14, this diﬀerence had
decreased to 2.5-fold (P<0.005). No signiﬁcant diﬀerences
inNP-speciﬁcIgtitersofCD18−/− andcontrolmiceoccurred
after rechallenge with the soluble antigen, from day 42
onwards (P>0.05). These results demonstrate a slight
shift in the kinetics of the primary immune response in
CD18−/− mutants, with an initial decrease in hapten-speciﬁc
IgG1 production, whereas primary NP-speciﬁc IgM were not
reducedinCD18−/− mice(datanotshown).However,overall
hapten-speciﬁc IgG peak titers mounted by CD18−/− mice
afterimmunizationwereinthesamerangeasinWTcontrols
showing that class switch as such was not impaired. After
boosting, ampliﬁcation of the immune response was as high
in CD18−/− as in WT mice reﬂecting a normal memory B-
cell generation and function. Besides, antibody composition
of either κ or λ light chains was comparable to those of WT
controls and revealed a marked prevalence of λ light chains
during the primary IgG response to NP, a typical feature of
the C57BL/6 mouse strain (data not shown) [30].Clinical and Developmental Immunology 5
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Figure 2: Functional humoral immune response upon NP-CG in CD18−/− mice. Eight- to twelve-week-old CD18−/− and WT mice were
immunized intraperitoneally with 100μg of alum-precipitated NP-CG. Animals were reinjected with 100μg of soluble NP-CG at day 34.
Sera were collected at days 0, 7, and 14 during primary immune response, and at days 34, 42, 49, and 56 during secondary immune response.
(a) Serum levels of anti-NP-speciﬁc IgG1 were subsequently detected by ELISA on NP4-coated ELISA plates and calculated by comparison to
an IgG1 standard. (b) Anti-NP-speciﬁc Ig carrying λ or κ L chains were diﬀerentially detected on high-density (NP14-BSA) and low-density
(NP4-BSA) hapten-coated ELISA plates in sera obtained at days 14, 34, and 56. Aﬃnity maturation of NP-speciﬁc antibodies was estimated
as ratio of NP4-t oN P 14-binding antibodies for each of the three time-points. Bars represent the median of each group. ∗∗P<0.005.
To determine aﬃnity maturation of NP-speciﬁc anti-
bodies, sera collected during the immunization trial were
analyzedfortheircontentsoflowandhighaﬃnityantibodies
for the hapten NP. Our data clearly demonstrate that aﬃnity
maturationoccurredtothesameextentinCD18−/− asinWT
mice, both showing a sharp increase in anti-NP aﬃnity after
repeated antigen challenge (P<0.05) (Figure 2(b)).
3.3. No Formation of Antigen-Speciﬁc GC after Immunization
with NP21-CG. CD18−/− mice have a severely disturbed
architecture of secondary lymphoid organs such as the
spleen and the lymph nodes [25, 28, 36]. Since adaptive
immunity in CD18−/− mice was nevertheless functional
upon immunization with NP21-CG, we set out to detect
germinal centers with speciﬁcity for the injected antigen
NP21-CG. To exclude artefacts skewing histological analysis
of CD18−/− mice, mice were used for histology at an age
of 8–12 weeks when lymphoid architecture had not yet
succumbed to secondary lymphoid and myeloid hyperplasia.
As described above, CD18−/− and control mice were injected
with 100μgN P 21-CG/alum. Secondary lymphoid tissues
were removed at day 14, when GC formation in mice is
at its maximum (Figure 3). Cryosections of WT spleens
showed typical germinal centers (GL-7+PNA+,I g D −IgM−)
with numerous GC that stained positive for the antigen NP-
CG coupled with Cy5 (NP-CG-Cy5) (Figures 3(a) and 3(b)).
In contrast to WT, CD18−/− mice had considerably fewer
GC, of a smaller size and altered structure. In addition,
none of the GC-like structures but only some disseminated
cells stained for the antigen NP21-CG in CD18−/− mutants.
Importantly, these cells were situated extrafollicularly and
were not organized in clusters as are GC.
Since no classical NP-CG-Cy5+ GC structures could be
detected in immunized CD18−/− mice by histology, whereas
IgG with high aﬃnity for NP21-CG was abundant in the sera,
we analyzed lymphoid tissues for NP-CG-Cy5+ c e l l sw i t ha
GC-like phenotype (CD19+GL7+ or CD19+PNA+)[ 32, 37]
by ﬂow cytometry (Figures 3(c) and 3(d)). As observed by
immunoﬂuorescent microscopy, NP21-CG immunized WT
revealed a prominent CD19+ B cell population that stained
for the GC marker GL-7, or PNA (data not shown), and
NP-CG-Cy5. In contrast, in CD18−/− mice, CD19+ B-cells
staining double positive for GL-7 and NP-CG-Cy5 were 5
t i m e sl e s sf r e q u e n tc o m p a r e dt oW Tm i c e( Figure 3(c)).
Hence, GC-like cells speciﬁc for NP-CG were present, but
without a distinct structural correlative in histology.
In case of altered lymphocyte traﬃcking and disrupted
secondary lymphoid tissue, BM can function as site of
primary immune response [38]. B cells, which have acquired
a typical PNA+ GC phenotype, have been described to seed
to the BM, where they further diﬀerentiate into antibody-
forming cells (AFCs) [39]. Thus, BM may, to some extent,
serve as a refuge for late B-cell development and maturation.










































Figure 3: No induction of GC with NP21-CG speciﬁcity after immunization in CD18−/− mice. Two weeks after immunization, spleens
and BM of WT and CD18−/− mice were subjected to immunoﬂuorescence microscopy (spleens; (a), (b)) or ﬂow cytometry (BM, spleens;
(c), (d)). B-cell follicles identify as IgD+ ( b )o rI g M + (a) (both in red), whereas GC locate within the follicles and stain IgD− GL-7+ (a)
or IgM− PNA+ (b) (GL-7 and PNA both in green). Speciﬁcity for NP-CG was assessed by staining with NP-CG-Cy5 (blue). (a) and (b)
show representative sections of spleens solely from immunized mice. Scale bars, 500μm. Spleen ((c); (d), upper histograms) or BM ((d),
lower histograms) cells were analyzed by FACS. (c) displays representative dot plots of splenic cells gated for CD19+ IgMlow. B cells with
a GC phenotype additionally stain positive for GL-7 and are situated in the right quadrants of each plot. GC B cells with speciﬁcity for
NP-CG are located in the upper right quadrants. Percentages for size-gated cells are indicated for immunized (upper dot plots) and mock-
immunized (lower dot plots) mice. (d) shows representative histogram plots of cells gated for CD19+ IgMlow GL-7+, representing GC B cells.
The continuous lines indicate samples obtained from mice immunized with NP21-CG; dashed lines: mock-immunized mice; grey areas:
irrelevant control conjugates.
CD18−/− mice, mononuclear cells were isolated from BM
andstainedforGCmarkers.OnlyveryfewCD19+IgMlowGL-
7+ cells could be detected using ﬂow cytometry. These
cells did not diﬀer in ﬂuorescence intensities for NP-CG-
Cy5 in NP21-CG immunized and nonimmunized cohorts,
neither in CD18−/− nor in WT mice (Figure 3(d)). Thus,
in CD18−/− mice no evidence for a compensatory function
of the BM in hosting GC-like cells was detected. Our data
reveal a ubiquitous deﬁciency for speciﬁc GC formation
upon immunization with NP21-CG in all lymphoid tissues
of CD18−/− mice subjected to analysis, postulating a salvage
mechanismoralternativepathwayingeneratinghigh-aﬃnity
AFC that yet remains unclear.
3.4. Eﬃcacy of the Immune Response Directly Correlates to the
Hapten/Protein Ratio of Antigens in CD18−/− Mice. To better
understand potential reasons for the in part contradictory
results obtained by immunization with NP21-CG and TT,
we modiﬁed our immunization protocols with regard to
antigen quantity and quality. Given the high dose of 100μg
NP21-CG administered in the initial trial, we repeated the
experiment with a low dose injecting 10μgN P 21-CG/alum
for the induction of primary immune responses, and 10μg
of soluble NP21-CG/PBS for boosting. Furthermore, to test
whether the degree of haptenation may be crucial for the
induction of a full immune response in CD18−/− mice, we
have used a reduced NP/CG ratio of 4/1, or nonhaptenated
CG without NP. This time, besides anti-NP speciﬁc IgG, also
anti-CG-speciﬁc IgG were determined from the sera to rule
out that in CD18−/− mice, hapten-speciﬁc responses may be
functional but carrier/protein directed IgG production, as,
for example anti-TT IgG, may be not. For this reason, sera
obtained during the initial immunization trial with 100μg
NP21-CG were additionally subjected to anti-CG IgG ELISA.Clinical and Developmental Immunology 7
AsshownbyFigure 4,CD18−/− micewerewellabletomount
anticarrier/protein-speciﬁc IgG titers to a similar extent as
they mounted antihapten-speciﬁc IgG titers if provided with
a suitable antigenic stimulus. Our studies demonstrate that
reduced anti-NP IgG levels (Figure 4(a)) were paralleled by
a decrease in anti-CG IgG levels (Figure 4(b)), both in WT
a n di nC D 1 8 −/− mice and preclude a general deﬁciency of
producing protein-speciﬁc antibody in our murine LAD1
model.
However, in contrast to WT, CD18−/− mice exhibited
a deﬁnite impairment in their primary and secondary
IgG responses upon decreased antigen quantity or hapten
coupling. Whereas upon doses as low as 10μgN P 21-CG,
CD18−/− mice revealed a signiﬁcant reduction of NP- and
CG-speciﬁc IgG production only during the secondary
immune response (P<0.05), a reduced NP/CG ratio of
4/1 (P<0.05), and more distinctly, uncoupled CG (P<
0.005) signiﬁcantly lowered antigen-speciﬁc IgG throughout
all time points analyzed. When the hapten/protein ratio was
decreased to 4/1, the gap between the CD18−/− and WT
cohort was more pronounced than after a mere reduction
of the antigen dose to 10μgN P 21-CG. Furthermore, even
after injection of a dose as high as 100μgn o n h a p t e n a t e d
CG, CD18−/− mice mounted only very poor anti-CG IgG
titers that remained more than 4 logs below the WT cohort,
also after boosting (Figure 4(b)). In the CD18−/− cohort
that had been administered 100μgN P 4-CG, anti-CG IgG
levels still were 3 logs below those of the WT cohort. Using
100μgN P 21-CG, CD18−/− mice produced anti-CG IgG at
WT levels. Altogether these data demonstrate a gradual
dependenceofadaptivehumoralimmunityinCD18−/− mice
onCGhaptenation.Thesedatafurthermoreindicatethatthe
deﬁciency in adaptive humoral immunity of CD18−/− mice
can be compensated by the amount of antigen injected for
immunization. However, haptenation of proteins is pivotal
and can eﬀectively rescue antigen-speciﬁc IgG production in
CD18−/− mice turning a weak protein antigen into a strong
immunogen in this system.
3.5. CD18−/− Mice Secrete Normal Levels of Anti-TT IgG
after Immunization with NP-TT. To test the validity of our
conclusions drawn from immunization with the haptenated
carrier NP-CG also for other T-dependent antigens, TT
vaccine was conjugated with NP, and subsequently used
for immunization as described above. Figure 5 shows a
slight initial delay of anti-TT IgG production at day 7
after ﬁrst injection of 2Lf NP-TT, reﬂecting results obtained
during the primary immune response to 100μgN P 21-CG.
At all later time points assessed, production of anti-TT
IgG in CD18−/− mice occurred at equal levels as in WT
mice, compared to immunization with 2Lf nonconjugated
TT, which had failed to induce suﬃciently high anti-TT
IgG titers. Collectively, these ﬁndings demonstrate, for the
ﬁrst time, that the elicitation of a full adaptive immune
response can be obtained upon immunization with a highly
haptenated TT analogue in complete absence of CD18. This
argues towards the use of highly haptenated antigens as
vaccines in LAD1.
4. Discussion
Eﬀective induction of an adaptive immune response relies
on a ﬁne-tuned orchestration of cell-cell interactions. This
requires integrity of functional as well as structural com-
ponents of the immune response. Despite the involvement
of CD18 in cognate interactions between APCs, T and B
lymphocytes, and a marked impairment of the adaptive
immune response in patients deﬁcient in CD18 (LAD1)
[23, 24, 35], we here report that a suitable, multivalent
antigenic stimulus can distinctly overcome the necessity of
CD18 for adhesion and intracellular signaling leading to a
robust antigen-speciﬁc humoral immune response in vivo.
Using the protein antigens CG or TT gradually haptenated
with NP as immunizing agents, we could induce a full
adaptive immune response in a murine model of LAD1.
This shows that CD18 is dispensable for the elicitation of a
complete adaptive immune response in vivo under the here
furtherdeﬁnedvaccinationconditions.Weheredemonstrate
that CD18 deﬁciency with speciﬁc defects in intercellular
adhesionrequiredforcellularcommunicationandactivation
at several stages of adaptive immunity can nevertheless be
overcome in CD18−/− mice in vivo by increasing antigen
concentrations or by modiﬁcation of antigen quality towards
carrier haptenation. These results are potentially valuable for
patients suﬀering from LAD1 or similar immunodeﬁciency.
A critical event in the initiation of adaptive immune
responses is the activation of T lymphocytes. LFA-1
(CD11a/CD18) is known to participate critically in the
biochemical and structural organization of immunological
synapses during T-cell activation [14]. It is a prerequisite
for a sustained TCR/MHC-peptide engagement [1, 3, 40]t o
achieve commitment to cytokine synthesis (IL-2, IFNγ)[ 9]
and T-cell proliferation [7, 8]. Accordingly, our previous in
vitro data showed that CD18−/− mice exhibited a severely
impaired activation of T-cells in MLR [25]. However, full T
cell activation was possible, when priming was done using a
suﬃcientamountofantigen,antigenicrestimulation[36],or
IL-2 substitution [36, 41].
We here show that the requirement for LFA-1 also in
T:B cell contacts is overall not essential for generating an
adaptive immune response in vivo. Our major ﬁnding is that
highly haptenated antigens do not depend on CD18 to elicit
complete adaptive immune responses. This may be due to
the fact that crosslinking of BCR does not require CD18.
Indeed, increasednumbers of epitopic binding sitesobtained
by multivalent haptenation cause a profound reduction in
both the minimal concentration and aﬃnity requisites for
B-cell activation [20, 42]. One key mechanism likely to
contribute to this phenomenon may be the marked increase
in IL-2 release due to an eﬃcient crosslinking of BCRs by
multivalently haptenated antigen [43, 44]. This may have
contributed to the rescue of the previously demonstrated
deﬁciency in IL-2 release in absence of LFA-1 or CD18
[9, 36, 41]. Accordingly, an enhanced release of IL-2 from
B cells due to crosslinking by polyhaptenated antigen may
have compensated for the intrinsic defect of CD18−/− Tc e l l s
to secrete IL-2. In addition, B-APC may be superior to DC
in antigen presentation and subsequent activation of CD4+8 Clinical and Developmental Immunology



















































































































CD18−/− (open symbols) and WT (ﬁlled symbols) mice were immunized intraperitoneally with 100μgo fN P 21-CG/aluM (squares), 10μg
NP21-CG/alum (circles), 100μgN P 4-CG/alum (triangles), or 100μg CG/alum (diamonds). (a) Serum levels of anti-NP speciﬁc IgG1 were
subsequently detected by ELISA on NP4-BSA coated ELISA plates and calculated in μg/mL by comparison to IgG1 standards, as described
above. (b) For detection of CG-speciﬁc IgG1, sera obtained by bleeding from tail veins were diluted 1:10, and then plated out on CG-coated
plates in 1:5 dilution steps. Serum titers of anti-CG-speciﬁc IgG1 were determined from the last dilution step where the optical density was
still above the background level of the assay. For assessment of the primary immune response, results from sera collected at days 7 and 28
are displayed. Besides, measurements for day 49 are shown, and depict IgG1 titers representative also for further time points assessed during
secondary immune responses. Bars represent the median of each group. ∗P<0.05; ∗∗P<0.005. Asterisks used in the key box indicate
signiﬁcant diﬀerences for the marked cohorts at all times points shown.
T cells upon encounter with protein antigen as compared to
peptide antigen [45]. Haptenated carriers even multiply this
eﬀect. Altogether, these mechanisms may contribute to the
herein observed eﬀect that polyhaptenated proteins help to
mount an eﬀective immune response even under conditions
of an impaired synapse formation in the absence of CD18.
Our results furthermore provide circumstantial evidence
that several redundant pathways may exist in vivo substitut-
i n gf o re a c ho t h e rt oo b t a i nas u ﬃcient immune response.
However, impairment of a distinct accessory pathway may
limit or suppress immune responses that were previously
robust by critically elevating activation thresholds, as has
been shown upon injection of TT in CD18−/− mice. Such
thresholds have earlier been described in detail for the
diﬀerent types of cellular interactions in vitro [1, 2, 5, 14,
36]. In vivo, also spatial availability of both lymphocytes
and APCs in a timely highly regulated fashion is pivotal
for the elicitation of adaptive immunity [46]. But with
regard to interstitial tissue locomotion of leukocytes (i.e.,
in three-dimensional environments), the role of CD18 (and
also of other integrins) seems to be rather limited [6,
47]. Nevertheless, in CD18−/− mice, structural integrity of
lymphoid organs is severely aﬀected [25]. This is most likely
due to impairments in cell traﬃcking in the context of
systemic leukocyte recirculation [27, 48, 49] and the overall
proinﬂammatory situation [28] in these mice.
Our data of an intact class switch and memory func-
tion support former reports. These reports revealed that
a structural integrity of GC, which have been commonly
called to account for class switch, aﬃnity maturation, and
memory B-cell generation [50, 51], is not compellingly
required to mount a full adaptive immune response [51–54].
Also, mice deﬁcient in Lyn kinase (LynK) exhibit absence of
GC combined with a widely functional humoral immune
response showing functional antibody production, class
switch, or even aﬃnity maturation [55]. Interestingly, both
CD18 and LynK, apart from costimulatory signaling, are
involved in cell-cell adhesion stabilizing membrane contacts
required for cognate synapses in GC [56].
Severalreportsrevealthatantigen-drivenclonalselection
of antibody-forming cells (AFCs) leading to an eﬀective
aﬃnity maturation of secreted Ig strictly requires Th:B cell
cooperation but can take place independently of classical
GC structures [32, 37, 52], even in compartments such as
the BM [33, 57, 58]. However, B-cells with GC phenotypic








































Figure 5: Adaptive immunity is functional upon immunization
with NP-TT in CD18−/− mice. Eight- to twelve-week-old CD18−/−
(open symbols) and WT (ﬁlled symbols) mice were immunized
intraperitoneally with 2.0Lf TT/alum (squares) or 2.0 Lf NP-
TT/alum. For measurements of anti-TT IgG1, blood was obtained
by bleeding from tail veins. Prior to analysis, sera were diluted
1 : 1 0 ,a n dt h e np l a t e do u to nT T - c o a t e dp l a t e si n1 : 5d i l u t i o n
steps. Serum titers of anti-TT-speciﬁc IgG1 were determined from
the last dilution step where the optical density was still above
the background level of the assay. For assessment of the primary
immune response, results from sera collected at days 7 and 34
are displayed. Besides, measurements for day 49 are shown, and
depictIgG1 titersrepresentativealsoforfurthertimepointsassessed
during secondary immune responses. Bars represent the median of
each group.
for AFC generation, independent of the respective type
of lymphoid tissue where the AFC emerge [32, 58]. B
cell maturation to AFC can be even achieved in vitro
without forming the typical complex GC structures but
still traversing intermediate stages with expression of GC
markers [59]. GC phenotypic cells with speciﬁcity for the
injected antigen were also detected in peripheral lymphoid
tissues of CD18−/− mice at low numbers, although classical
GC with an analogous speciﬁcity remained absent. Besides,
careful examination revealed no hints for a compensatory
hosting of GC structures or cells in the BM of CD18−/− mice.
We therefore conclude that disseminated GC-phenotypic
cells were functional in mediating an adaptive immune
response including a normal aﬃnity maturation of antibody
in CD18−/− mice.
In summary, our data suggest that functional adaptive
immunity in murine LAD1 depends on speciﬁc properties
oftheemployedimmunogen.Demonstratingthatabsenceof
CD18 largely reduces the spectrum of suitable immunogens,
our data provide further insight into the role of β2 integrins
in adaptive immunity yielding novel results with regard
to the complex in vivo situation. Based on our data, we
suggest that distinct features of an immunization with highly
haptenated NP conjugates only could lead to a rescue
of function, though not to a rescue of structure with
immunogen-speciﬁc GC remaining absent. Our data may
stimulate further investigations in LAD1 patients.
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